In patients with atrial fibrillation who were unable to receive warfarin for any reason, the use of apixaban reduced the risk of stroke and systemic embolism when compared to aspirin. Study Rundown: Atrial fibrillation is a common arrhythmia that increases the risk of stroke and. AVERROES has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety. AVERROES. Apixaban Versus ASA. To Reduce the Risk Of Stroke. Coordinated by Population Health Research institute. Hamilton, Ontario, Canada. Sponsors.

Author: Yohn Moogunris
Country: Zimbabwe
Language: English (Spanish)
Genre: Technology
Published (Last): 2 August 2010
Pages: 411
PDF File Size: 2.61 Mb
ePub File Size: 2.41 Mb
ISBN: 748-3-93161-802-7
Downloads: 50683
Price: Free* [*Free Regsitration Required]
Uploader: Kinris

Usable articles Cardiology Neurology. The median duration of follow-up was 1. Retrieved from ” http: Mortality rates were 3.

VKA therapy not recommended by the physician; Also, how does apixaban compare to aspirin rates of major bleeding? AVERROES on the other hand has shown that the new oral anti-Xa inhibitor apixaban is superior to aspirin in terms of efficacy, with surprisingly similar safety.

The AVERROES Trial – Clinical Implications

It has multiple theoretical benefits over VKA therapy including less intensive monitoring and fewer drug averrles. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation.


Based on the indirect comparison with ACTIVE A, one should conclude that apixaban is, at the time of writing, the best alternative to aspirin ever found in patients deemed unsuitable for VKAs. Patients also needed to have at least one of the following risk factors for stroke: Presented as apixaban vs. Concurrent medications whose metabolism could be affected by VKAs; 9. Notes to editor Correspondence: Expected difficulty in contacting patient for urgent change in dose of VKAs; 6.

Apixaban is a novel oral anticoagulant that inhibits factor Xa.

The AVERROES Trial – Clinical Implications

In patients with atrial fibrillation thought to be unsuitable candidates for anticoagulation with a vitamin K antagonist, apixaban signficantly reduced the risk of stroke and systemic embolism without increasing the risk of major bleeding or intracranial hemorrhage when compared to aspirin. One may question each of these choices: Apixaban in Patients with Atrial Fibrillation. Adverse event not related to bleeding during VKA therapy; 3.

Yet, these proportions reflect the current underuse of VKAs in multiple registries.


Eur Heart J ; There were 44 1. To reduce the burden of cardiovascular disease. The New England Journal of Medicine.

AVERROES – Wiki Journal Club

Read your latest personalised notifications Sign in No account yet? Did you know that your browser is out of date? Its role in prevention of stroke in patients unsuitable for VKA therapy, but maintained on apixabam therapy, was unknown. J Am Coll Cardiol ; The trial was terminated early given a treatment benefit with apixaban.

In April the Data and Safety Monitoring Board recommended early study termination because of clear benefit in favor of apixaban. All these reasons can be grouped in three broad categories: Of the patients enrolled, reasons for being deemed unsuitable for VKA therapy included the following: With a mean follow-up of 1.

This proportion was similar for both academic and community hospitals. Views Read View source View history.

work_outlinePosted in Food